NNC0385-0434

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameNNC0385-0434
Drug Alias NameNNC0385-0434NN-6435NNC 0385 0434
ClassificationBiologics
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemiaDiabetes Mellitus, Type 2Atherosclerosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/S
Inactive CompaniesN/A
Active IndicationsHypercholesterolemiaDiabetes Mellitus, Type 2Atherosclerosis +[4] 
Inactive IndicationsCardiovascular DiseasesRenal Insufficiency, Chronic

Other Information

ATC CodeN/A
Related LinksN/A